A controlled trial of antihypertensive therapy in systemic sclerosis (scleroderma).
Antihypertensive treatment may be life saving in scleroderma renal crisis. Patients surviving such crises frequently have had dramatic improvement in the dermal manifestations of their scleroderma. To investigate the potential role of antihypertensive treatment in nonhypertensive patients we randomly assigned 28 patients with systemic sclerosis into drug (14) and placebo (14) groups, using blocked randomisation , and followed them up in a prospective, double-blind clinical trial for 24 months. Overall, both groups improved slightly, with both subjective and objective markers. There were no statistically significant differences and no clinically meaningful trends between the 2 groups, except that the blood pressure was reduced in the group on the active drug.
This article has been cited by other articles:
-
Furst, D. E., Clements, P. J., Wong, W. K., Mayes, M. D., Wigley, F., White, B., Weisman, M., Barr, W., Moreland, L., Martin, R., Medsger, T. A. Jr, Steen, V., Collier, D., Weinstein, A., Lally, E., Varga, J., Weiner, S. R., Andrews, B., Abeles, M., Peter, J. B., Seibold, J. R.
(2001). Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial. Rheumatology (Oxford)
40: 615-622
[Abstract] [Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
